Disease · EFO_1002009
macular telangiectasia type 2
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. macular telangiectasia type 2. Diseases, record EFO_1002009. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1002009
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- macular telangiectasia type 2
- Open Targets ID
- EFO_1002009
- Other names
- MacTel, idiopathic juxtafoveal retinal telangiectasis type 2
- Highest stage of its drugs
- Phase 3, for 3 of its 5 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs5
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CILIARY NEUROTROPHIC FACTOR | CHEMBL4298063 | Phase 3 | ClinicalTrials.gov | 5 | 4 | 3 | Drugs and targets | |
| REVAKINAGENE TARORETCEL | CHEMBL5314636 | Gene | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| SERINE | CHEMBL11298 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| FENOFIBRATE | CHEMBL672 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ZEAXANTHIN | CHEMBL2359248 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets1
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes |
|---|---|---|---|---|---|
| PPARA | Peroxisome proliferator-activated receptor alpha | 1 | Peroxisome proliferator-activated receptor alpha agonist | Phase 2 | https://conductscience.org/library/genes/5465 |
Source Drugs and targets
Trials8
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03316300 | A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A | Phase 3 | 120 | 2024-09-24 | Macular Telangiectasia Type 2 (MacTel) | REVAKINAGENE TARORETCEL | Its record names the disease | ClinicalTrials.gov |
| NCT03319849 | A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol B | Phase 3 | 119 | 2024-09-24 | Macular Telangiectasia Type 2 | REVAKINAGENE TARORETCEL | Its record names the disease | ClinicalTrials.gov |
| NCT04729972 | Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2 | Phase 2 | 33 | 2025-03-26 | Macular Telangiectasia Type 2 | CILIARY NEUROTROPHIC FACTOR | Its record names the disease | ClinicalTrials.gov |
| NCT07342439 | Study of Serine Supplementation to Protect Vision in MacTel | Phase 3 | 120 | Macular Telangiectasia Type 2 (MacTel) | SERINE | Its record names the disease | ClinicalTrials.gov | |
| NCT04907084 | Serine and Fenofibrate Study in Patients With MacTel Type 2 | Phase 2 | 89 | Macular Telangiectasia Type 2 | FENOFIBRATE, SERINE | Its record names the disease | ClinicalTrials.gov | |
| NCT01949324 | A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel | Phase 2 | 67 | Macular Telangiectasia Type 2 | CILIARY NEUROTROPHIC FACTOR | Its record names the disease | ClinicalTrials.gov | |
| NCT01354093 | The Role of Macular Pigment Carotenoids in the Pathogenesis and Treatment of Macular Telangiectasia Type 2 (MacTel) | 8 | Idiopathic Juxtafoveal Telangiectasia | ZEAXANTHIN | Its record names the disease | ClinicalTrials.gov | ||
| NCT01327911 | Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel) | Phase 1 | 7 | Idiopathic Juxtafoveal Telangiectasia | CILIARY NEUROTROPHIC FACTOR | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| NT-501 vs Sham: deaths from any cause | 0 of 58 | 1 of 57 | 115 | NCT03316300 | Trial comparisons |
| NT-501 vs Sham: serious adverse events | 12 of 58 | 7 of 57 | 115 | NCT03316300 | Trial comparisons |
| NT-501 vs Sham: deaths from any cause | 1 of 59 | 0 of 54 | 113 | NCT03319849 | Trial comparisons |
| NT-501 vs Sham: serious adverse events | 11 of 59 | 10 of 54 | 113 | NCT03319849 | Trial comparisons |
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_1002009
GET https://conductscience.org/api/diseases/v1/EFO_1002009/drugs